思路迪医药股份二零二五年中期报告

2025 INTERIM REPORT中期報告 Contents 2Definitions7Corporate Information10Business Highlights14Financial Summary18Management Discussion and Analysis52Other Information71Independent Review Report73Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income74Interim Condensed Consolidated Statement of Financial Position76Interim Condensed Consolidated Statement of Changes in Equity77Interim Condensed Consolidated Statement of Cash Flows80Notes to Interim Condensed Consolidated Financial Information BOARD OF DIRECTORS Executive Director Dr. Gong Zhaolong(Chairman of the Board) Non-executive Directors 20256302025630 Mr. Zhu Pai (resigned on June 30, 2025)Mr. Zhou FengMs. Chen YawenMr. Zhu Jinqiao (was appointed on June 30, 2025) Independent Non-executive Directors Dr. Li JinDr. Lin Tat PangMr. Liu Xinguang REMUNERATION COMMITTEE Mr. Liu Xinguang(Chairman)Dr. Gong ZhaolongDr. Li Jin NOMINATION COMMITTEE 20253312025331 Dr. Gong Zhaolong(Chairman)Dr. Li JinMr. Liu XinguangMs. Chen Yawen (was appointed on March 31, 2025)Dr. Lin Tat Pang (was appointed on March 31, 2025) AUDIT COMMITTEE 20256302025630 Dr. Lin Tat Pang(Chairman)Mr. Zhu Pai (resigned on June 30, 2025)Dr. Li JinMr. Zhou Feng (was appointed on June 30, 2025) JOINT COMPANY SECRETARIES Ms. Xia FangMs. Li Ching Yi AUTHORISED REPRESENTATIVES Dr. Gong ZhaolongMs. Li Ching Yi Corporate Information公司資料 PRINCIPAL BANK 15822F3 Bank of CommunicationsShanghai Minhang Sub-branch22F, Block 3, Jiefang TowerNo. 158 Zhucheng RoadMinhang District, ShanghaiPRC COMPANY WEBSITE www.3d-medicines.com www.3d-medicines.com REGISTERED OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands CORPORATE HEADQUARTERS 35 No. 3 and No. 5, Laiyang RoadQingdao, Shandong, PRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 19th Floor, Golden Centre188 Des Voeux Road CentralHong Kong 18819 PRINCIPAL SHARE REGISTRAR ANDTRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong Corporate Information公司資料 LEGAL ADVISERS As to Hong Kong and U.S. laws 131 O’Melveny & Myers31/F, AIA Central1 Connaught Road CentralHong Kong As to PRC law Zhong Lun Law Firm6/10/11/16/17F, Two IFC8 Century AvenuePudong New AreaShanghaiPRC 86/10/11/16/17 As to Cayman Islands law 829 Conyers Dill & Pearman29th Floor One Exchange Square8 Connaught PlaceCentralHong Kong AUDITOR AND REPORTING ACCOUNTANT 28814B Modern Assure CPA LimitedCertified Public AccountantsRegistered Public Interest Entity AuditorsUnit B, 14/F, Eton Building288 Des Voeux Road CentralSheung WanHong Kong STOCK CODE 12441244 Business Highlights 2025ETF In the first half of 2025, Hong Kong’s capital market showed signsof recovery, with a significant uptick in the performance of biotech-focusedETFs.As an innovation-driven biopharmaceutical companyinthe commercialization phase,3D Medicines capitalized on thisfavorable market environment to achieve substantial progress. mRNA Over the past 6 months, we have strategically aligned our R&D effortswithfuture clinical needs,making disciplined investments in early-stageresearch.Envafolimab’s indication expansion research hasbeen carried out smoothly, and many varieties of nuclear drugs andmRNA platforms with global independent intellectual property rightsare being promoted to clinical research. L o o k i n ga h e a d ,w e h a v e s t a b l e r e v e n u e ,a n d m e t a l l k e yR&Dmilestones,our commitment to breakthrough innovationremainsunwavering.We have strengthened our global strategicpartnerships,working closely with collaborators to advance theoverseascommercialization of our products.These initiativesmarkthe beginning of a new chapter for 3D Medicines–onedefinedby innovation-driven growth and global expansion.Theseaccomplishments collectively laid a robust foundation for us to enter anew stage of dual-driven growth and global innovation. THE ONGOING DEVELOPMENT OF OUR FIRSTCOMMERCIALIZED PRODUCT 2 0 2 563 0 In particular, during the six months ended June 30, 2025 and up tothe date of this interim report: •®PD-L12025630209.21.3% •®,as the only commercially available subcutaneously-injectable PD-L1 inhibitor in China, achieved sales revenue ofRMB209.2 million in China for the six months ended June 30,2025,representing a 1.3%increase compared to the sameperiod last year. •®hasthe 19th recommendation in authoritative clinicalguidelineand consensus recommendations both domesticallyand internationally. •®19 •2025(ASCO)11 •Att